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SUMMARY
The extracellular matrix (ECM) can induce chemotherapy resistance via AKT-mediated inhibition of
apoptosis. Here, we show that loss of the ECM protein TGFBI (transforming growth factor beta in-
duced) is sufficient to induce specific resistance to paclitaxel and mitotic spindle abnormalities in
ovarian cancer cells. Paclitaxel-resistant cells treated with recombinant TGFBI protein show integ-
rin-dependent restoration of paclitaxel sensitivity via FAK- andRho-dependent stabilization ofmicro-
tubules. Immunohistochemical staining for TGFBI in paclitaxel-treated ovarian cancers from a pro-
spective clinical trial showed that morphological changes of paclitaxel-induced cytotoxicity were
restricted to areas of strong expression of TGFBI. These data show that ECM can mediate taxane
sensitivity by modulating microtubule stability.
Open access under CC BY-NC-ND license.INTRODUCTION
Taxanes are microtubule-stabilizing drugs that have been
extensively used as effective chemotherapeutic agents in
the treatment of solid tumors (McGuire et al., 1996; San-
dler et al., 2006). However, taxane resistance limits clinical
utility to approximately 50% of patients with breast or
ovarian cancer. Identification of mechanisms of taxane514 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Iresistance that are therapeutically accessible is, therefore,
required to improve treatment.
Paclitaxel, a prototype taxane, stabilizes microtubule
polymers leading to mitotic arrest and apoptosis (Schiff
et al., 1979; Ibrado et al., 1998; Scatena et al., 1998). Gen-
eral mechanisms of drug resistance, including overex-
pression of the ABC/MDR transporter family of proteins
(Peer et al., 2004), delayed G2/M transition (Tan et al.,SIGNIFICANCE
Extracellular matrix (ECM) proteins such as fibronectin induce resistance to chemotherapy via activation of intra-
cellular survival pathways. We now show that the ECM protein TGFBI mediates specific sensitization to paclitaxel
by inducing stabilization of microtubules via integrin-mediated signaling pathways. Analysis of paclitaxel-treated
ovarian cancers from a prospective clinical trial shows TGFBI protein expression in areas of paclitaxel-induced
cytotoxicity. Bioinformatic analysis of three microarray expression data sets from 223 ovarian and breast cancer
samples show that TGFBI expression is tightly coregulated with other genes that induce paclitaxel sensitization
such as THBS1. These data show that paclitaxel response can be modulated by ECM proteins and raise the pros-
pect of improving the therapeutic index of taxanes via manipulation of these proteins and their downstream sig-
naling pathways.nc.
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TGFBI Sensitizes Ovarian Cancers to Paclitaxel2002), defective mitotic checkpoints (Anand et al., 2003),
and alterations in apoptosis regulation (Huang et al.,
1997), may alter paclitaxel sensitivity. More specifically,
alterations of microtubules induce severe taxane resis-
tance (Zhang et al., 1998; Gonc¸alves et al., 2001; Alli
et al., 2002; Wang et al., 2004). These include b-tubulin
mutations which may decrease paclitaxel binding to mi-
crotubules (Giannakakou et al., 1997). Alternatively, fac-
tors that increase the ratio of unstable to stable microtu-
bules induce profound taxane resistance. This may
occur by mutations in nonpaclitaxel binding sites, alter-
ations in tubulin isoforms (Gonc¸alves et al., 2001; Barlow
et al., 2002; Hari et al., 2006), overexpression of b-III tubu-
lin (Mozzetti et al., 2005), and overexpression of the micro-
tubule-associated protein stathmin (Alli et al., 2002).
Cells contain subsets of stable and dynamic microtu-
bules that are functionally distinct (Gundersen et al.,
1984), and there is strong evidence that extracellular stim-
uli regulate microtubule stability. Serum starvation or loss
of direct cell contact results in loss of microtubule stabili-
zation, while fibronectin-mediated adhesion or treatment
of cells with lysophosphatidic acid or TGFb induce micro-
tubule stability (Cook et al., 1998; Palazzo et al., 2004;
Gundersen et al., 1994). Whether extracellular matrix
(ECM) modulation of microtubule stability may alter pacli-
taxel sensitivity has been, to date, unknown.
We describe here the identification of TGFBI (transform-
ing growth factor beta induced) as an ECM protein that in-
duces microtubule stabilization and modulates paclitaxel
sensitivity in vitro and in patients receiving paclitaxel
therapy.
RESULTS
TGFBI Is Significantly Underexpressed
in an Ovarian Cancer Cell Line Model
of Paclitaxel Resistance
To identify genes associated with the acquisition of pacli-
taxel resistance, we studied the ovarian cancer cell line
SKOV-3TR, which was derived from SKOV-3 by pro-
longed and repeated exposure to increasing doses of
paclitaxel (Duan et al., 1999). We compared the expres-
sion profiles of the parent and resistant lines using cDNA
microarrays (Figure 1A) after confirming that SKOV-3
and SKOV-3TR were isogenic by short tandem repeats
genotyping (data not shown). Examination of the most dif-
ferentially expressed genes showed several candidates
previously identified in chemotherapy response including
CP, SOD2 (Ueta et al., 2001), HMGA1 (Huang et al.,
1994; Kasparkova et al., 2003), and CXCL1 (Taxman
et al., 2003) (Figure 1A; Table S1 in the Supplemental
Data available with this article online).
The most underexpressed gene in the taxane-resistant
line was transforming growth factor beta induced (TGFBI;
also known as Big-h3, b-ig H3, and keratoepithelin), which
is an extracellular matrix protein whose secretion is in-
duced by TGFb1 stimulation (Skonier et al., 1992). Its func-
tions include cell adhesion to the ECM and integrin-medi-
ated signaling (Jeong and Kim, 2004; Billings et al., 2002).CanQuantitative real-time PCR confirmed striking underex-
pression (>1000 fold) of TGFBI (Figure 1B). This underex-
pression was maintained after growing the cells without
paclitaxel for several months (data not shown). Immuno-
cytochemistry using anti-TGFBI antibody on paraffin-em-
bedded cell blocks and immunoblotting of conditioned
media from the two cell lines showed very low secretion
of TGFBI protein (Figures 1C and 1D) from the resistant
SKOV-3TR cells.
Loss of TGFBI Is Sufficient to Induce Paclitaxel
Resistance
To examine the effect of loss of TGFBI expression on pac-
litaxel sensitivity, stable transfected cell lines expressing
short interfering RNAs (siRNA) against TGFBI were gener-
ated from the parental SKOV-3 line. Two vectors targeting
21 bp sequences at nucleotides 810 or 1318 of the TGFBI
coding sequence were transfected independently or to-
gether to generate stable cell line pools SKOV3-A,
SKOV3-K, and SKOV3-AK, respectively. Effective knock-
down (KD) of TGFBImRNA and protein was achieved in all
three lines (Figures 1B and 1D and data not shown).
The effect of paclitaxel treatment on these cells was ex-
amined. Early apoptosis was measured after 48 hr of pac-
litaxel exposure by flow cytometry of cells stained with
FITC-annexin V and 7-AAD (Wang et al., 1998). Cell lines
that lacked TGFBI (SKOV-3TR and TGFBI-KD cells)
showed a significantly lower percentage of paclitaxel-in-
duced apoptosis (p < 0.001, one-way ANOVA) in contrast
to control SKOV-3 cells (Figure 1E). Caspase 3/7 activa-
tion 48 hr following paclitaxel treatment was significantly
reduced in SKOV-3TR and TGFBI-KD cells (p < 0.001,
two-way ANOVA) (Figure 1F) as was caspase 3 cleavage
(Figure S1A).
Analysis of 9 ovarian and 11 breast cancer cell lines
showed that TGFBI expression was significantly lower in
resistant (n = 7) cells (p = 0.027, two-way ANOVA), and
this was independent of cell type (Figures S1B and
S1C). Importantly, transient knockdown of TGFBI using
a pool of four siRNAs in four additional ovarian cancer
cell lines, OVCAR3 (Figure 1G), TR175 (Figure 1H), 1847
(Figure S1D), and PE01 (Figure S1E), resulted in significant
resistance to paclitaxel-induced caspase activation (p <
0.001, two-way ANOVA). These results were confirmed
using at least two individual siRNAs in each cell line
(data not shown).
SKOV-3TR cells have accumulated multiple paclitaxel
resistance mechanisms during in vitro selection (Lamen-
dola et al., 2003). For example, expression profiling of
SKOV-3TR shows upregulation of MDR1 and ABCB6
(Duan et al., 2005; data not shown). The intensity values
of a fluorescent derivative of paclitaxel were lower in
SKOV-3TR compared to parental SKOV-3 and could be
corrected using the MDR1 inhibitor verapamil (Fig-
ure S2A). However, induction of paclitaxel resistance in
SKOV-3 cells by specific downregulation of TGFBI
strongly suggested that TGFBI was an important compo-
nent of the resistance shown in SKOV-3TR.cer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc. 515
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TGFBI Sensitizes Ovarian Cancers to PaclitaxelFigure 1. Loss of TGFBI Is Sufficient to Induce Paclitaxel Resistance
(A) Volcano plot shows log fold change in gene expression in the paclitaxel-resistant cell line SKOV-3TR compared to the sensitive parental line
SKOV-3 and plotted against the likelihood of differential expression. Note that negative log2 expression ratios indicate underexpression in
SKOV-3TR. Data points represent the probability value for differential gene expression and data shown is from four replicate experiments.
(B) Relative expression levels of TGFBI in different cell lines using real time PCR.
(C) Immunocytochemistry of stained sections from embedded cell pellets using anti-TGFBI antibody. Scale bars, 10 mm.
(D) Western blotting of culture medium from SKOV-3TR, mock-transfected SKOV-3, and TGFBI siRNA-transfected SKOV3-K cell lines probed with
anti-TGFBI antibody.
(E) Effect of stable KD of TGFBI (SKOV3-A, SKOV3-K, and SKOV3-AK) on paclitaxel-induced apoptosis measured by FITC-annexin V and 7-AAD
staining at 48 hr following paclitaxel treatment (150, 300, 600, 1200, and 2000 nM) compared to SKOV-3, mock-transfected SKOV-3 (mtSKOV3),
and SKOV-3TR cells. Filled triangle indicates increasing paclitaxel dose across each group of bars.
(F) Effect of stable KD of TGFBI on caspase 3/7 activation 48 hr following paclitaxel treatment.
(G and H) Transient TGFBI-KD in OVCAR3 and TR175 lines induces paclitaxel resistance. Caspase 3/7 activation was estimated 48 hr following trans-
fection using either a pool of 4 siRNAs targeting TGFBI or nontargeting scrambled controls (sc). OVCAR3 cells (G) or TR175 cells (H) were treated with
paclitaxel for 48 hr. Immunoblot confirming knockdown of TGFBI protein is shown in (G). Error bars show mean ± SD.516 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc.
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TGFBI Sensitizes Ovarian Cancers to PaclitaxelTo investigate how TGFBI modulated response to pac-
litaxel, we analyzed common resistance mechanisms us-
ing TGFBI-KD cells. Intracellular intensity of fluorescent
paclitaxel was not different after TGFBI-KD (Figure S2A).
In addition, apoptosis induction using UV, cisplatin, or no-
codazole treatment was not significantly different be-
tween TGFBI-KD and parental cells (Figure S2B). These
data show that paclitaxel resistance arising from specific
loss of TGFBI is not caused by nonspecific alterations in
apoptotic or multi-drug-resistance pathways.
Abnormal mitotic checkpoints have previously been
shown to confer paclitaxel resistance (Anand et al.,
2003). Mitotic SKOV-3 cells lacking TGFBI showed a slight
increase in prophase (Figure S2C), but no significant dif-
ference in the duration of mitotic progression was ob-
served when measured by time-lapse imaging of individ-
ual cells (p = 0.1, one-way ANOVA, Figure S2D). A
characteristic feature of overriding mitotic checkpoints is
persistence of checkpoint proteins following metaphase
(Anand et al., 2003). Figure S2E shows no significant dif-
ference (p = 0.4, Chi Square test) between KD and control
cell lines in the proportion of postmetaphase cells showing
persistent cyclin B1 staining. BubR1, a mitotic checkpoint
protein expressed prior to anaphase, is thought to sense
tension across the spindle when chromosomes are
aligned in the metaphase plate (Nicklas, 1997). Correct
sensing of spindle tension leads to degradation of
BubR1 and anaphase transition. Spindle poisons such
as nocodazole and paclitaxel abolish tension leading to
persistent expression of BubR1 (Logarinho et al., 2004).
Cells with abnormal BubR1 function progress to anaphase
in spite of exposure to spindle poisons. The expression of
BubR1 in wild-type, KD, and SKOV-3TR cells was normal
following nocodazole treatment indicating that sensing of
spindle tension was not impaired (Figure S2F). Delayed
cell-cycle transition has been shown to confer paclitaxel
resistance (Tan et al., 2002). There was no difference in
cell-cycle profiles of nonsynchronized TGFBI-KD or
SKOV-3TR cells as compared to mock-transfected
SKOV-3 (data not shown). To test cell-cycle profiles in
synchronized cells, we used HeLa cells as they express
comparable levels of TGFBI to those of SKOV-3 (data
not shown) and are a well characterized cell-cycle model
with intact mitotic checkpoints and are sensitive to pacli-
taxel (Anand et al., 2003). Figure S2G shows that transient
knockdown of TGFBI had no effect on cell-cycle progres-
sion in HeLa cells synchronized in G1 by double thymidine
block.
TGFBI Restores Paclitaxel-Induced Tubulin
Polymerization
Microtubule bundle formation has been described as the
hallmark of paclitaxel exposure in vivo (Schiff and Horwitz,
1980) and is lost in resistant cells (Giannakakou et al.,
1997). Indeed, SKOV-3 cells treated with 2 mM paclitaxel
for 24 hr showed striking paclitaxel-induced bundles
(PIBs) in interphase cells (Figures 2A and 2B and
Figure S3A) and severe failure of mitotic spindle organiza-
tion. Mitotic cells showed a prometaphase-like stateCanwhere chromosomes formed ring-like structures around
centrally radiating microtubule fibers, which we termed
mitosis-like wheels (MLWs) (Figure S3B). In contrast, a mi-
nority of SKOV-3TR cells showed PIBs (2.4% versus 93%)
or MLWs (1.7% versus 92%) (Figures 2C and 2D and
Figure S3A). Importantly, SKOV-3TR cells transfected
with a myc-tagged TGFBI expression plasmid (pCSMT-
TGFBI) showed a modest increase (12% versus 3.7%) in
the proportion of PIBs and MLWs following paclitaxel
treatment (p < 0.001, two-sided t test) (Figures 2E and
2F and Figure S3A).
Paclitaxel induces microtubule stabilization, and post-
translational modifications of tubulin, such as detyrosina-
tion or acetylation, accumulate in these stable microtu-
bules. Detyrosination exposes Glu residues at the
carboxy terminus of alpha-tubulin that can be detected
using antibodies and, therefore, used as a marker of mi-
crotubule stability (Gundersen et al., 1984). Cells lacking
TGFBI (SKOV-3TR, SKOV3-K) showed impaired pacli-
taxel-induced microtubule stabilization as evidenced by
decreased Glu-tubulin formation following paclitaxel
treatment (Figure 2G). Similarly, transient TGFBI-KD of
SKOV-3 using pooled siRNAs resulted in intermediate re-
duction of paclitaxel induced Glu-tubulin (Figure 2G).
These data suggest that selective loss of TGFBI induces
paclitaxel resistance at the level of microtubules. Alter-
ation of microtubule function leading to paclitaxel resis-
tance is associated with increased ratios of soluble to in-
soluble intracellular tubulin (Gonc¸alves et al., 2001;
Barlow et al., 2002; Hari et al., 2006). Consistent with
this, SKOV-3TR and SKOV3-K cells showed increased
soluble tubulin compared to parental SKOV-3 cells (Fig-
ures 2H and 2I).
TGFBI Silencing Results in Increased Mitotic
Abnormalities in Cancer Cell Lines
Tight regulation of tubulin dynamics is crucial for normal
completion of mitosis, and alterations in microtubules
that induce taxane resistance can cause geometric defor-
mities in the mitotic spindle (Gonc¸alves et al., 2001; Kline-
Smith and Walczak, 2004). Mitotic cells from SKOV-3TR
had a significantly higher proportion of abnormal mitosis
compared to control SKOV-3 cells (14% versus 1.9%, re-
spectively; p < 0.001, two-way ANOVA) (Figure 3C). To
confirm that loss of TGFBI was sufficient to induce mitotic
abnormalities, we examined the effects of TGFBI knock-
down on mitosis in SKOV3-K and SKOV3-A cells. Strik-
ingly, abnormal mitotic figures were observed including
monopolar spindle formation, multiple centrosomes with
multipolar spindles (Figure 3A), and abnormal spindle ar-
chitecture (Figure 3B) in stably transfected cells 9–30
days following transfection. Control cells transfected
with empty vector and examined in parallel at the same
time points did not show significant mitotic abnormalities
(Figure 3C). In addition, interphase cells showed a signifi-
cant increase in the proportion of cells with centrosome
amplification (Figure 3D). These phenotypes were also ob-
served 48 hr after transient TGFBI-KD of HeLa, 1847, and
OVCAR3 cell lines and also in SKOV-3 using A810 andcer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc. 517
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TGFBI Sensitizes Ovarian Cancers to PaclitaxelFigure 2. Loss of TGFBI Causes Defec-
tive Paclitaxel-Induced Microtubule Po-
lymerization
(A–F) Overexpression of TGFBI in SKOV-3TR
by pCSMT-TGFBI sensitizes microtubules to
the polymerizing effect of paclitaxel. Arrow-
heads indicate paclitaxel-induced bundles
(PIBs). Green, tubulin; blue, Dapi-stained
DNA. Scale bars, 10 mm.
(G) Paclitaxel induces Glu-tubulin formation.
Cells were serum starved for 24 hr then treated
with paclitaxel in serum-free medium (SFM) at
0, 4, 16, 75, 300, and 1200 nM concentrations
for 1 hr. Lysates were collected for fluores-
cence immuno-blotting with anti-Glu-tubulin
and anti-alpha tubulin. Bars represent the fold
increase in Glu-tubulin fluorescence intensity
values normalized for alpha-tubulin intensity
values. Filled triangle indicates increasing pac-
litaxel dose across each group of bars.
(H) A fluorescence immunoblot of soluble (sol)
and insoluble (insol) tubulin fractions.
(I) SKOV-3TR and SKOV3-K cells have in-
creased soluble tubulin. Graph shows the per-
centages of soluble tubulin in relation to total
tubulin in the different cell lines. Quantitative
measurements were performed using fluores-
cence immunoblotting with anti-alpha tubulin
antibody as described in Supplemental Exper-
imental Procedures. Results shown are from
two independent experiments. Horizontal bars
indicate median values.K1318 constructs, although lower proportions of abnor-
mal mitoses were seen (Figure 3E and data not shown).
To examine whether direct colocalization of TGFBI with
microtubules or centrosomes could explain these find-
ings, we characterized the subcellular localization of car-
boxy-terminal tagged TGFBI (with green fluorescent pro-
tein or myc epitopes). Tagged-TGFBI localized in the
Golgi apparatus and in intracellular vesicles along micro-
tubule fibers and accumulated at cellular protrusions con-
sistent with secretion (Figure S4). No tagged-TGFBI was
seen in the nucleus of interphase cells and there was no
localization in mitosis to spindle poles, spindle fibers, or
condensed chromosomes.
rTGFBI Protein Promotes Cell Adhesion
and Microtubule Stabilization
Integrin-mediated adhesion of cells to fibronectin induces
microtubule stabilization (Palazzo et al., 2004), suggesting
that ECM and paclitaxel might have additive effects on mi-
crotubules. The stabilizing effect of fibronectin requires in-
tegrin-mediated focal adhesion kinase (FAK) activation
and Rho A (Palazzo et al., 2004). TGFBI is known to medi-518 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Iate adhesion also in an integrin-dependent manner (Bill-
ings et al., 2002; Nam et al., 2003; Jeong and Kim, 2004;
Park et al., 2004). This suggested a model where TGFBI
could modulate paclitaxel sensitivity via microtubule sta-
bilizing effects (Figure 4A). rTGFBI promoted adhesion of
SKOV-3 cells, and this effect was partially antagonized
by pretreating cells with a blocking antibody to alphaV-
beta3 integrin (Figures S5A and S5B) (p < 0.001, two-sided
t test).
Figure 4B shows that cells plated on rTGFBI showed
a significant increase in Glu-tubulin formation indicating
microtubule stabilization (Gundersen et al., 1984; Palazzo
et al., 2004). In addition, adhesion of cells to rTGFBI, or
fibronectin, induced phosphorylation of FAK (Figure 4C).
Attachment to fibronectin, but not to the integrin-indepen-
dent adhesion peptide polylysine (PL), also showed
Glu-tubulin formation (Figure 4D). To test whether FAK
was required for microtubule stabilization by rTGFBI, we
knocked down FAK in SKOV-3 cells using siRNAs, and
these cells showed a significant decrease in microtubule
stabilization following adhesion to rTGFBI (Figure 4E)
(p < 0.001, two-sided t test). To test whether Rho A wasnc.
Cancer Cell
TGFBI Sensitizes Ovarian Cancers to Paclitaxelalso required for rTGFBI microtubule stabilization, Rho A
was specifically inactivated using the cell permeable in-
hibitor C3 toxin. This resulted in a significant decrease in
microtubule stabilization following adhesion to rTGFBI
(Figure 4F) (p < 0.001, two-sided t test). These data con-
firmed that rTGFBI induced microtubule stabilization and
that this required intact FAK and Rho A signaling. Exten-
sion of these experiments to nonmalignant cells using
Figure 3. Loss of TGFBI Induces Mitotic Abnormalities
(A and B) Stable KD of TGFBI in SKOV-3 cells results in abnormal mi-
totic spindle formation and centrosome amplification. Magenta, tubu-
lin; blue, Dapi-stained DNA; yellow, gamma tubulin.
(C) Proportion of abnormal mitotic cells at 9–30 days in SKOV-3TR,
stable knockdown, and mock transfected (mt) cell line pools.
(D) Proportion of interphase cells showing centrosome amplification.
Number of cells counted is shown above corresponding bars.
(E) Proportion of abnormal mitotic cells after 48 hr following transient
knockdown of TGFBI using a pool of four siRNAs. Error bars show
mean ± SD.CancNIH 3T3 fibroblasts also showed that rTGFBI induced
Glu-tubulin formation and FAK phosphorylation (Fig-
ure S5C). In addition, inactivation of Rho in NIH 3T3 cells
using a dominant-negative Rho A expression construct
significantly reduced the rTGFBI-mediated stabilization
of microtubules (Figure S5D).
rTGFBI Protein Sensitizes TGFBI-KD Cells
to Paclitaxel in an Integrin-Dependent Manner
To test whether extracellular TGFBI was able to sensitize
cells to the effect of paclitaxel, SKOV3-A and SKOV3-K
cells were plated on rTGFBI-coated wells. This signifi-
cantly increased paclitaxel-induced apoptosis (p < 0.001,
two-way ANOVA) (Figure 5A). Importantly, KD of TGFBI
significantly reduced the slope of the dose response curve
for paclitaxel-induced Glu-tubulin formation (KD cells
slope 1.3, 95% C. I. 0.6–2.1 versus SKOV-3 control cells
slope 2.8, 95% C. I. 2.2–3.4) (Figures 5B and 5C). Plating
KD cells on rTGFBI restored the slope of Glu-tubulin for-
mation (slope 2.4, 95% C. I. 1.6–3.1) (Figures 5B and 5C
and Figure S5E). SKOV-3TR cells plated on rTGFBI and
treated with paclitaxel showed only a modest increase in
apoptosis (data not shown), which we attributed to lower
intracellular paclitaxel concentrations (Figure S2A). In-
creasing the level of intracellular paclitaxel by inhibiting
paclitaxel efflux using verapamil significantly increased
the sensitizing effect of rTGFBI in SKOV-3TR (Figure 5D).
Verapamil also increased formation of stable microtubules
in SKOV-3TR cells plated on rTGFBI following treatment
with paclitaxel (Figure 5B). Control SKOV-3 cells plated
on rTGFBI without paclitaxel treatment did not show in-
creased caspase 3/7 activity (data not shown). We then
tested whether rTGFBI was able to sensitize other pacli-
taxel-resistant ovarian cancer cells that had not been se-
lected in vitro for resistance (see also Figure S1B). Figures
5E and 5F show that rTGFBI significantly increased pacli-
taxel-induced caspase activation in A2780 and PE0188
cells (p < 0.001, two-way ANOVA).
Incubation of TGFBI-KD cells in serum-free media con-
ditioned with rTGFBI also resulted in a significant reversal
of paclitaxel resistance (p < 0.001 one-way ANOVA)
(Figure 5G and Figure S5F). To test whether this sensitiza-
tion was integrin dependent, we pretreated SKOV3-K cells
with anti-alphaVbeta3 blocking antibody before exposure
to rTGFBI-conditioned media. This pretreatment signifi-
cantly reduced paclitaxel-induced apoptosis (p < 0.001,
one-way ANOVA), confirming that rTGFBI binding to al-
phaVbeta3 was required for paclitaxel sensitization
(Figure 5G and Figure S5F). To examine whether microtu-
bule stabilization was required for rTGFBI-mediated pac-
litaxel sensitization, we blocked Rho and FAK pathways
downstream of rTGFBI-integrin binding. Pretreatment
with C3 toxin of SKOV3-KD cells for 4 hr before paclitaxel
treatment decreased the sensitizing effect of rTGFBI
(Figure 5G and Figure S5F). Similarly, transient knock-
down of FAK using a single siRNA blocked the sensitizing
effect of rTGFBI in Figure 5G and Figure S5F.
FAK induces proliferation and survival in cancer cells,
and therefore, downregulation of FAK was expected toer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc. 519
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TGFBI Sensitizes Ovarian Cancers to PaclitaxelFigure 4. TGFBI Induces Microtubule Stabilization
(A) Model of TGFBI induction of microtubule stabilization.
(B) Microtubule stabilization demonstrated with anti-Glu tubulin antibody. SKOV-3 cells were plated for 90 min on rTGFBI or polylysine-coated glass
slides (20 mg/ml) before immunofluorescence. Scale bars, 10 mm.520 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc.
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TGFBI Sensitizes Ovarian Cancers to Paclitaxelsensitize cells to chemotherapy (Judson et al., 1999; Sood
et al., 2004). However, FAK is required for ECM-induced
microtubule stabilization (Palazzo et al., 2004), and our
data suggested that loss of FAK might also induce pacli-
taxel resistance. We have recently shown using a RNAi
screen for all kinases (in which, therefore, TGFBI was
not included) that loss of FAK (PTK2) and its family mem-
ber PTK2B induced paclitaxel resistance in A549 non-
small-cell lung carcinoma and HCT116 colon cancer cells,
respectively (Swanton et al., 2007). Transient knockdown
of FAK in SKOV-3 and breast cancer MDA-MB-231 cells
(defined as paclitaxel sensitive, Figure S1B) using
independent siRNAs also induced significant resistance
to paclitaxel-mediated apoptosis (p < 0.001, two-way
ANOVA) (Figure S5G and data not shown). In addition, inhi-
bition of Rho A resulted in resistance to paclitaxel induced
apoptosis (Figure S5H). These results show that perturb-
ing components of pathways involved in microtubule sta-
bility is sufficient to induce paclitaxel resistance.
TGFBI Is Tightly Coexpressed with Fibronectin
In parallel with the in vitro work, we carried out a prospec-
tive randomized clinical trial (CTCR–OV01) specifically de-
signed to examine the molecular response to carboplatin
and paclitaxel monotherapy in patients with advanced
ovarian cancer. Tumor samples were collected prior to the
start of neoadjuvant therapy and at subsequent interval
debulking surgery (Supplemental Data and Figure S6A).
As TGFBI is an integral component of the ECM, we in-
vestigated whether TGFBI expression correlated with
the expression of other ECM transcripts that signal via in-
tegrins. We performed a correlation analysis between the
expression of TGFBI and all other informative genes on the
array (n = 3426), across all samples derived from patients
treated with paclitaxel (n = 20), and ranked the genes ac-
cording to their level of correlation with TGFBI. Strikingly,
18 out of the 20 top ranked genes were ECM-related
genes (Table S2). Notably, these genes included fibronec-
tin (FN1) (r = 0.89, Pearson correlation), collagen 5A1
(COL5A1) (r = 0.83, Pearson correlation), and thrombo-
spondin-2 (THBS2) (r = 0.88, Pearson correlation).
THBS1 is a homolog of THBS2 and was recently found
to induce paclitaxel sensitivity through extracellular sig-
naling (Lih et al., 2006). There was a significantly positive
correlation between the probability of a gene being
ECM-related and its degree of coexpression with TGFBI
(r = 0.89, Pearson correlation; p < 0.001, linear regression)
(Figure 6A).
To confirm this finding in external data sets, we ana-
lyzed published expression microarray data from ovarian
and breast cancers (Spentzos et al., 2005; Naderi et al.,Can2007). Coregulation of TGFBI with ECM genes was repro-
duced with striking similarity (Figure 6B and data not
shown). Importantly, the top ranked coexpressed genes
in these independent sets consistently included fibronec-
tin and THBS2. THBS1 was also highly ranked in the
Spentzos ovarian cancer data set (data not shown).
TGFBI Is Underexpressed in Paclitaxel-Resistant
Primary Ovarian Carcinoma Tissues
To determine whether TGFBI expression was associated
with clinical paclitaxel resistance, we analyzed microarray
expression data from twenty patients randomized to pac-
litaxel monotherapy in CTCR-OV01. Patients who showed
paclitaxel resistance, as indicated by CA125 monitoring,
had a significantly lower expression of TGFBI (p = 0.046,
Wilcoxon test; 3.9% false discovery rate). RNA from
16/20 samples was available for real-time PCR. Patients
who showed no paclitaxel response had a significantly
lower expression of TGFBI (p = 0.0087, n = 16, Wilcoxon
test) in their pretreatment samples compared to those
who responded (Figure 6C).
Centrosome Amplification Is Present in
Paclitaxel-Resistant Ovarian Cancer Samples
As loss of TGFBI resulted in spindle deformities and cen-
trosome amplification, we examined whether centrosome
amplification correlated with paclitaxel resistance in clini-
cal samples. To accurately count centrosomes in samples
from the clinical study, we used three-dimensional recon-
structions of confocal images from 20 mm tissue sections.
Adequate amounts of tumor tissue were available in 10
pretreatment samples. Reconstructed images were scored
by rotating the image to count the number of centrosomes
associated with each nucleus (Figure 6D and Movie S1).
Using this method, a total number of 2376 nuclei were
examined in 10 cancer samples, and counting was per-
formed blind to the clinical outcome of patients. We found
a significantly higher (p = 0.019, Wilcoxon test) proportion
of cells with centrosome amplification in paclitaxel-resis-
tant patients (7.6%) compared to paclitaxel responders
(3.9%) (Figure 6E).
Paclitaxel-Induced Cell Death in Ovarian Cancer
Samples Colocalizes with Areas of High TGFBI
Protein Expression
We next examined ovarian cancer samples taken after
paclitaxel treatment from the CTCR-OV01 study using
immunohistochemistry for TGFBI. Sections of ovarian
cancer tissue revealed morphological changes typical of
paclitaxel-induced cytotoxicity, including cytoplasmic
vacuolation and multinucleation (Seiler et al., 2004), and(C) Cells were adhered to polylysine, fibronectin, or rTGFBI-coated wells (20 mg/ml) for 90 min before lysates were collected for immunoblotting using
anti-phosphorylated FAK (P397). Also shown are immunoblots for lysates of cells treated in suspension with or without paclitaxel at 3 mM.
(D) Percentages of SKOV-3 cells showing Glu-tubulin following adhesion to rTGFBI, fibronectin, or polylysine.
(E) 48 hr following transfection using either FAK siRNA or nontargeting siRNAs, SKOV-3 cells were plated on rTGFBI coated glass slides for 90 min and
the percentage of cells showing Glu-tubulin formation was estimated by immunofluorescence.
(F) SKOV-3 cells were either treated with the Rho A inhibitor C3 toxin in SFM or with SFM alone for 4 hr before plating on rTGFBI-coated glass slides
and estimation of Glu-tubulin formation. Error bars show mean ± SD.cer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc. 521
Cancer Cell
TGFBI Sensitizes Ovarian Cancers to PaclitaxelFigure 5. rTGFBI Sensitizes Resistant Cells to the Effect of Paclitaxel
(A) Cells were adhered to rTGFBI-coated wells (20 mg/ml) or noncoated wells for 24 hr prior to paclitaxel treatment for 48 hr. Shown is the percentage
of apoptotic cells as measured using FITC-annexin V and 7-AAD staining.
(B) Cells were serum starved for 24 hr then treated with paclitaxel in serum-free medium (SFM) at 0, 4, 16, 75, 300, and 1200 nM concentrations for
1 hour before lysates were collected for fluorescence immunoblotting using anti-Glu-tubulin and anti-alpha tubulin. Bars represent the fold increase
in glu-tubulin fluorescence intensity values normalized for alpha tubulin intensity values. Filled triangle indicates increasing paclitaxel dose across
each group of bars.
(C) The slope and 95% confidence intervals for the linear regression of Glu-tubulin formation following paclitaxel treatment in SKOV-3 and mtSKOV3
(SKOV3-WT), SKOV3-A and SKOV3-K (SKOV3-KD), and SKOV3-KD following plating on rTGFBI.
(D) SKOV-3TR cells were either plated on plastic or rTGFBI as in (A) and either treated with paclitaxel alone (SKOV3-TR) or with paclitaxel and verap-
amil 3.3 mM (TR + V and TR + V + rTGFBI) for 48 hr before caspase 3/7 activity was estimated. Also shown is the data for the parental sensitive line
(SKOV-3) plated on plastic.
(E and F) A2780 Cells (E) or PE0188 cells (F) were either plated on plastic or on rTGFBI (20 mg/ml) before paclitaxel treatment for 48 hr. Shown is the fold
increase in caspase 3/7 activity.
(G) Cells were either pretreated with 50 mg/ml of rTGFBI in SFM or SFM alone for 2 hr followed by paclitaxel treatment for 1 hr, washing, and incubation
in full media for 48 hr. Shown is the percentage of apoptotic cells measured by FITC-annexin V and 7-AAD staining. A+rTGFBI+anti-alphaVbeta3;
SKOV3-A cells pretreated with anti-alphaVbeta3 in SFM before treatment with rTGFBI and paclitaxel, A+rTGFBI+FAK-KD; SKOV3-A cells were trans-
fected with siRNA targeting FAK 48 hr prior to rTGFBI and paclitaxel treatment, A+rTGFBI+C3-toxin; SKOV3-A cells were pretreated with the Rho A
inhibitor, C3 toxin, in SFM for 4 hr before the application of rTGFBI and paclitaxel. Error bars show mean ± SD.these changes were localized to areas of high TGFBI stain-
ing (Figure 6F and Figures S6B and S6C). TGFBI labeling
was absent in the ECM around neighboring cells lacking522 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Ipaclitaxel-induced changes and in areas of necrosis (Fig-
ure 6F and Figure S6D). Positive TGFBI staining was sig-
nificantly associated with evidence of paclitaxel-inducednc.
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TGFBI Sensitizes Ovarian Cancers to PaclitaxelFigure 6. The ECM Protein TGFBI Sensitizes Ovarian Carcinoma Cells In Vivo to the Effect of Paclitaxel
Correlation between expression of TGFBI and ECM genes in (A) CTCR-OV01 study and (B) independent ovarian cancer data set from Spentzos et al.
(2005). Graphs show proportion of ECM-related genes increasing as a function of coexpression with TGFBI. (C) TGFBI expression in pretreatment
biopsies of advanced ovarian carcinoma using real-time PCR. Resistant cases (n = 5; magenta) are compared to sensitive cases (n = 11; green).
(D) Three-dimensional reconstruction of Z stack images obtained following double immunofluorescent staining of a representative ovarian carcinoma
tissue section. Arrowheads indicate amplified centrosomes in a single cell confirmed by examination in all three planes. Anti-g tubulin, green; chro-
mosomal DNA, Hoechst 33258 red. Scale bar, 10 mm. (E) Centrosome amplification is associated with paclitaxel resistance. Centrosome counting
was performed on samples from which adequate frozen tissue was available (n = 10; samples common between [C] and [E] are indicated by squares).
In (C) and (E), horizontal bars indicate median values. (F) Immunohistochemistry for TGFBI of representative posttreatment ovarian cancer sample.
Paclitaxel-induced morphological changes colocalize with focal TGFBI expression (brown staining, green box 1) but not in areas of low TGFBI
expression (magenta box 2). Scale bars for main subfigure and boxes, 500 mm and 50 mm, respectively.Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Inc. 523
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TGFBI Sensitizes Ovarian Cancers to Paclitaxelcytotoxicity (n = 14, p = 0.0035, Chi square test with
Monte-Carlo simulation). Importantly, focal TGFBI staining
was present in pretreatment samples; however cytoplas-
mic vacuolation and multinucleation were not seen
(Figure S6E).
DISCUSSION
Our results suggest that the ECM protein TGFBI modu-
lates paclitaxel response via regulation of microtubule sta-
bility. Acetylated and detyrosinated microtubules define
a stable subpopulation of microtubule polymers that resist
depolymerization (Gundersen et al., 1984). This popula-
tion is less dynamic compared to unstable microtubules
and, therefore, less likely to contribute to the proportion
of depolymerized tubulin in the cell (Figure 7). As paclitaxel
primarily targets polymerized microtubules, an increase in
the proportion of unstable microtubules induces paclitaxel
resistance (Gonc¸alves et al., 2001; Barlow et al., 2002;
Hari et al., 2006). We show that extracellular TGFBI stabi-
lized microtubules and increased sensitivity to paclitaxel.
Conversely, selective loss of TGFBI by KD resulted in mi-
totic spindle abnormalities and paclitaxel resistance.
These findings mimic previous results from cell lines with
intracellular alterations of tubulin that also caused pacli-
taxel resistance and mitotic instability (Gonc¸alves et al.,
2001; Martello et al., 2003). TGFBI was originally identified
as induced by TGFb stimulation in adenocarcinoma cells
(Skonier et al., 1992), and our results may explain how
TGFb induces microtubule stabilization in serum-starved
fibroblasts (Gundersen et al., 1994). Recombinant TGFBI
induced microtubule stabilization that was dependent on
integrin-mediated FAK and Rho signaling. The exact
mechanisms of microtubule stabilization downstream of
FAK and Rho remain unknown but may include mDIA1
or inactivation of the microtubule associated protein stath-
min (Palazzo et al., 2004; Baldassarre et al., 2005).
The relationship between ECM proteins and drug resis-
tance is likely to be complex. Previous studies have shown
that ECM proteins induced resistance to DNA-damaging
drugs such as cisplatin and etoposide, and decreased
apoptosis was associated with b1-integrin-mediated acti-
vation of PI3K and AKT (Sethi et al., 1999; Hodkinson
et al., 2006). In contrast, the ECM protein THBS1 sensi-
tizes pancreatic cancer cells specifically to taxane-
induced apoptosis in a CD47-dependent manner (Lih
et al., 2006). Here, we show that TGFBI is tightly coex-
Figure 7. Proposed Model of Modulation of Paclitaxel Resis-
tance by TGFBI via Effects on Microtubule Stability524 Cancer Cell 12, 514–527, December 2007 ª2007 Elsevier Inpressed with THBS1 in ovarian and breast cancers. It is
possible that the two proteins may cooperate to induce
taxane sensitization through activating CD47-driven path-
ways (THBS1) and integrin-mediated microtubule stabili-
zation (TGFBI). The finding that the protein expression
of TGFBI in tissue samples treated with paclitaxel mono-
therapy, specifically colocalized with areas of taxane-
induced cytotoxicity suggests that TGFBI, and possibly
other ECM proteins, modulate taxane effects in vivo. Our
data extend previous reports and suggests that the spe-
cific molecular targets of individual drugs are likely to de-
termine whether the effect of the ECM is agonistic or an-
tagonistic with chemotherapy.
Importantly the findings reported here have potentially
significant clinical implications. First, TGFBI protein ex-
pression is lost in a third of primary ovarian cancers
(A.A.A., A.E.K.I., and J.D.B., unpublished data) and TGFBI
has previously been shown to be methylated and downre-
gulated in lung cancer (Shao et al., 2006; Zhao et al.,
2006). Future studies should correlate the expression of
TGFBI with taxane response to test the value of TGFBI
as a predictive biomarker. Second, in ovarian cancer,
FAK is overexpressed, plays a role in regulating invasion
and metastasis, and is associated with poor clinical out-
come (Judson et al., 1999; Sood et al., 2004). FAK also
regulates tumor growth either directly, through activation
of ERK-dependent pathways (Hecker et al., 2002), or indi-
rectly through inducing angiogenesis (Sheta et al., 2000).
Downregulation of FAK using siRNAs results in inhibited
growth and metastasis of pancreatic cancer (Duxbury
et al., 2004) and could, therefore, be attractive therapeuti-
cally. However, previous studies have demonstrated that
FAK is required for adhesion-dependent microtubule sta-
bilization (Palazzo et al., 2004). In the current study, loss of
FAK or Rho A blocked microtubule stabilization and pac-
litaxel sensitization by rTGFBI. Importantly, and in contrast
to previous publications (Halder et al., 2005), our results
show that loss of FAK results in increased resistance to
taxanes, and this was confirmed using independent
siRNAs and experimental studies (Swanton et al., 2007).
As FAK is low or absent in one-third of patients with ovar-
ian cancer (Sood et al., 2004), it could be used as a marker
to identify patients who may not benefit from paclitaxel
treatment. Furthermore, although downregulation of FAK
may also induce growth inhibition, our data argue against
combining FAK inhibitors with paclitaxel treatment.
We describe here a mechanism of specific paclitaxel
sensitization via induction of microtubule stabilization by
the ECM protein TGFBI. Furthermore, we show that ex-
pression of TGFBI in ovarian and breast tumors is tightly
coregulated with other ECM proteins that either induce
microtubule stabilization or paclitaxel sensitization. The
effectiveness of taxanes in improving survival in ovarian
cancer remains controversial (International Collaborative
Ovarian Neoplasm Group, 2002), and TGFBI could be
used as a biomarker for selecting patients for taxane ther-
apy. In addition, as TGFBI is an ECM protein, activating
peptides or antibodies that mimic its action may be a strat-
egy for modulation of response to taxane chemotherapy.c.
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Cambridge Translational Cancer Research Ovary 01 Study
The details of this study are described in Supplemental Experimental
Procedures. The study was approved by the Cambridge Local Re-
search Ethics Committee (LREC). All patients gave written informed
consent prior to participation.
Cell Culture
Cell lines were obtained from Cell Services (Cancer Research UK Lon-
don Research Institute) and were maintained in RPMI 140 medium
supplemented with 10% fetal bovine serum, penicillin, and streptomy-
cin and incubated at 37C and 5% CO2. SKOV-3TR cells were main-
tained in 0.3 mM paclitaxel.
Apoptosis Assays, Annexin V Binding, and Flow Cytometric
Analyses
Cells were grown in 6-well plates to 80% confluence before paclitaxel,
nocodazole, cisplatin, or verapamil treatment (Sigma). For rTGFBI pre-
treatment experiments, adherent cells in 24-well tissue culture plates
were incubated with rTGFBI at 50 mg/ml in serum-free media (SFM)
for 2 hr followed by paclitaxel treatment for 1 hr to make up the required
concentrations. Cells were then washed with PBS and incubated with
normal media for 48 hr. For integrin-blocking experiments, attached
cells were incubated with the mouse monoclonal antibody anti-
alphaVbeta3 (Chemicon) for 1 hr (1 in 100 dilution) in SFM. Rho A inhi-
bition in SKOV-3 cells was achieved by treating attached cells with
2 mg/ml cell permeable C3 transferase recombinant protein (Cytoskel-
eton) in SFM for 4 hr prior to paclitaxel treatment for 1 hr. Early apopto-
sis was estimated using apoptosis detection kit (R & D systems) and
7-AAD (Molecular Probes) following the manufacturers’ instructions
and as previously described (Wang et al., 1998). Flow cytometric anal-
ysis was performed with a LSR II flow cytometer (BD bioscience) and
analyzed with the FACSDiva software (BD bioscience).
Caspase 3 and 7 Assays
We first confirmed the optimum number of cells and linear range for
paclitaxel dose response for the assay. Cells were plated at 1 3 104
cells per well in a 384-well plate in 20 ml volume overnight before pac-
litaxel was added in 10 ml volume to reach the final indicated concen-
trations. Caspase 3/7 activity was estimated 48 hr following treatment
by adding 30 ml of the Caspase-Glo 3/7 Assay reagent (Promega). Lu-
minescence was read following at least 1 hr of incubation on a lumines-
cence plate reader (Infinite M200, Tecan) using the i-control software
(Tecan).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, five supplemental figures, two supplemental tables, and one
supplemental movie and can be found with this article online at
http://www.cancercell.org/cgi/content/full/12/6/514/DC1/.
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